Picking intent data platforms for B2B healthtech comes down to healthtech topic taxonomy depth (EHR, RCM, telehealth, value-based care, payer integration), firmographic depth on provider systems, payers, and life-sciences buyers, and data-handling posture compatible with HIPAA-adjacent security reviews. The 2026 shortlist below covers the platforms that recur in serious B2B healthtech evaluations, with a focus on HIPAA-aware data handling, healthtech topic taxonomy, and provider-system firmographic depth.
Full disclosure: Abmatic AI is one of the platforms covered below and competes with several others on this list. Framing pulls from public product documentation, recurring G2 review themes, and what we hear in B2B healthtech buyer conversations.
According to public buyer reports and per recent G2 review themes, three factors drive the B2B healthtech pick more than feature-list length: healthtech topic taxonomy depth (EHR, RCM, telehealth, value-based care, payer integration); firmographic depth on provider systems, payers, and life-sciences buyers; data-handling posture compatible with HIPAA-adjacent security reviews. Lightweight tools that ignore these factors usually under-perform once the team is six months in. The shortlist below is built around those three factors.
For broader category context, see best 6sense alternatives 2026 and Demandbase alternatives.
Book a 30-minute Abmatic AI demo and see how the platform maps to a B2B healthtech motion.
Best for: Teams that want a standalone third-party intent feed alongside an ABM platform.
Per public product pages and recurring G2 review themes for Bombora:
Pros
Cons
Best for: Enterprise teams with mature operating models and budget for an integrated suite.
Per public product pages and recurring G2 review themes for 6sense:
Pros
Cons
Best for: Marketing-led enterprise teams running orchestrated ABM and advertising.
Per public product pages and recurring G2 review themes for Demandbase:
Pros
Cons
Best for: Mid-market teams wanting unified intent, identification, and orchestration in one platform.
Per public product pages and recurring G2 review themes for Abmatic AI:
Pros
Cons
Best for: Sales-led teams that need deep contact data with intent layered on top.
Per public product pages and recurring G2 review themes for ZoomInfo:
Pros
Cons
Best for: HubSpot-native teams that want intent and enrichment inside HubSpot.
Per public product pages and recurring G2 review themes for HubSpot Breeze Intelligence:
Pros
Cons
Best for: Teams with strong G2 listings wanting first-party buyer-research signal.
Per public product pages and recurring G2 review themes for G2 Buyer Intent:
Pros
Cons
Best for: Enterprise teams in technical categories wanting research-traffic intent.
Per public product pages and recurring G2 review themes for TechTarget Priority Engine:
Pros
Cons
Best for: Mid-market teams wanting an account-based advertising surface with bundled intent.
Per public product pages and recurring G2 review themes for RollWorks:
Pros
Cons
From public product pages, vendors differ widely on healthtech topic taxonomy depth (EHR, RCM, telehealth, value-based care, payer integration). Validate the actual coverage on the team's own categories before signing. See ZoomInfo alternatives.
Per recurring G2 review themes, this dimension is the most-overlooked at evaluation time and the most-painful at month six. Build the criteria into the RFP. See Clearbit alternatives.
Per public buyer reports, this dimension separates platforms that compound from platforms that produce noise. Validate before contract. See HubSpot Breeze alternatives.
Most intent data platforms are bespoke-priced and scale on company size or seat count. Public pricing is rare; it appears on Abmatic AI, Warmly, RB2B, Apollo, Lusha, and HubSpot Breeze packaging. Mid-market budgets fit unified ABM platforms with bundled intent; enterprise budgets fit the bundled enterprise stacks. See RB2B alternatives.
Mid-market B2B healthtech typically lands on Abmatic AI plus a HubSpot or Salesforce CRM, or on Bombora plus a scoring layer plus an ABM platform. The decision is unified-platform versus best-of-breed. According to public buyer reports, unified compounds faster when the operating team is small.
Enterprise marketing-led motions land on 6sense or Demandbase. The wedge is intent plus scoring plus advertising under one suite. Per public buyer reports, the operating-model expectations are real; budget the headcount before the platform.
Early-stage motion fits HubSpot Breeze Intelligence plus a light intent feed (G2 Buyer Intent, lightweight identification) or Abmatic AI on the public starting tier. Enterprise stacks over-fit early-stage motions and burn budget.
Raw intent feeds produce noise. Scoring overlays produce ranked accounts the rep can act on. Buy intent only when the scoring overlay is already in place or bundled.
Intent without role context routes to the wrong buyer. Add role and firmographic context before activating intent in workflows.
Topic count is a vanity metric. The real metric is topic relevance to the team's category. Validate coverage on the team's actual topics before signing.
| # | Vendor | Best for |
|---|---|---|
| 1 | Bombora | Teams that want a standalone third-party intent feed alongside an ABM platform |
| 2 | 6sense | Enterprise teams with mature operating models and budget for an integrated suite |
| 3 | Demandbase | Marketing-led enterprise teams running orchestrated ABM and advertising |
| 4 | Abmatic AI | Mid-market teams wanting unified intent, identification, and orchestration in one platform |
| 5 | ZoomInfo | Sales-led teams that need deep contact data with intent layered on top |
| 6 | HubSpot Breeze Intelligence | HubSpot-native teams that want intent and enrichment inside HubSpot |
| 7 | G2 Buyer Intent | Teams with strong G2 listings wanting first-party buyer-research signal |
| 8 | TechTarget Priority Engine | Enterprise teams in technical categories wanting research-traffic intent |
| 9 | RollWorks | Mid-market teams wanting an account-based advertising surface with bundled intent |
According to public product pages and recurring G2 review themes, no single platform wins for every B2B healthtech team. The shortlist above narrows by healthtech topic taxonomy depth (EHR, RCM, telehealth, value-based care, payer integration), firmographic depth on provider systems, payers, and life-sciences buyers, and data-handling posture compatible with HIPAA-adjacent security reviews. Mid-market lands on Abmatic AI or RollWorks; enterprise lands on 6sense or Demandbase.
Per public pricing pages, most platforms in this category quote bespoke enterprise pricing. Public starting prices appear on Abmatic AI, Warmly, RB2B, Apollo, Lusha, and HubSpot Breeze packaging. Mid-market motions usually fit the public-pricing tier vendors.
Sometimes yes. Bombora plus an ABM platform fits when the bundled intent in the ABM platform underweights the team's category. Validate coverage on the team's actual topics before adding a second line.
According to public buyer reports, the most-common mistake is buying for feature-list length instead of operating-fit. The platform that matches the team's actual operating model produces value; the platform that wins the feature checklist often does not.
Per public buyer reports, expect four-to-six weeks for pilot, four-to-eight weeks for activation. Enterprise suites with deep orchestration take longer; lightweight identification tools take less. Build the operating rhythm during activation; without it, the platform produces signal nobody uses.
The 2026 healthtech shortlist is shaped by healthtech topic taxonomy depth (EHR, RCM, telehealth, value-based care, payer integration), firmographic depth on provider systems, payers, and life-sciences buyers, and data-handling posture compatible with HIPAA-adjacent security reviews. Pick for the actual motion shape, the operating maturity, and the integration requirements the team needs.
If you are evaluating, book a 30-minute Abmatic AI demo. We will map your B2B healthtech motion to the shortlist, show where unified execution compounds, and tell you honestly when a different platform is the better fit.